{
  "@context": "http://credreg.net/ctdl/schema/context/json",
  "@id": "http://lr-staging.learningtapestry.com/resources/ce-FA703602-05DA-4C4A-BD96-A2A40148AD15",
  "@type": "ceterms:AssessmentProfile",
  "ceterms:assesses": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 1. Blood Group Systems",
      "ceterms:targetNodeDescription": "1) Basic\n2) Molecular\n3) Inheritance of blood groups\n4) Applied\n5) Parentage ",
      "ceterms:targetNodeName": "A. Genetics"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 1. Blood Group Systems",
      "ceterms:targetNodeDescription": "1) ABO\n2) Lewis\n3) Rh\n4) MNS\n5) P, Globoside\n6) Ii\n7) Kell\n8) Kidd\n9) Duffy\n10) Lutheran\n11) Other\n12) Antigens of high incidence\n13) Antigens of low incidence\n14) HLA\n15) Platelet specific\n16) Granulocyte specific ",
      "ceterms:targetNodeName": "B. Chemistry, Antigens "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 1. Blood Group Systems",
      "ceterms:targetNodeDescription": "1) Immunogenicity\n2) Antigen frequency ",
      "ceterms:targetNodeName": "C. Role of Blood Groups in Transfusion "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 2. Antibody Screen and Identification",
      "ceterms:targetNodeName": "A. Antibody Screen "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 2. Antibody Screen and Identification",
      "ceterms:targetNodeDescription": "1) Duffy\n2) Ii\n3) Kell\n4) Kidd\n5) Lewis\n6) MNS\n7) P\n8) Rh\n9) Multiple antibodies ",
      "ceterms:targetNodeName": "B. Antibody Identification"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 3. Crossmatch and Special Tests",
      "ceterms:targetNodeName": "A. Crossmatch"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 3. Crossmatch and Special Tests",
      "ceterms:targetNodeDescription": "1) DAT\n2) Phenotyping and genotyping\n3) Elution/adsorption\n4) Antibody titer\n5) Pre-warm technique\n6) Rosette and Kleihauer-Betke ",
      "ceterms:targetNodeName": "B. Special Tests"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 4. Blood Donation, Transfusion Therapy, Transfusion Reactions and Hemolytic Disease of the Fetus and Newborn (HDFN) ",
      "ceterms:targetNodeDescription": "1) Donor requirements\n2) Donor testing ",
      "ceterms:targetNodeName": "A. Blood Donation"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 4. Blood Donation, Transfusion Therapy, Transfusion Reactions and Hemolytic Disease of the Fetus and Newborn (HDFN) ",
      "ceterms:targetNodeDescription": "1) RBC\n2) PLT\n3) FFP\n4) Cryoprecipitated AHF\n5) RhIG ",
      "ceterms:targetNodeName": "B. Transfusion Therapy "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 4. Blood Donation, Transfusion Therapy, Transfusion Reactions and Hemolytic Disease of the Fetus and Newborn (HDFN) ",
      "ceterms:targetNodeName": "C. Transfusion Reactions"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "BLOOD BANK (17-22% of total exam) - 4. Blood Donation, Transfusion Therapy, Transfusion Reactions and Hemolytic Disease of the Fetus and Newborn (HDFN) ",
      "ceterms:targetNodeName": "D. HDFN "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 1. Carbohydrates, Acid Base and Electrolytes ",
      "ceterms:targetNodeDescription": "1) Glucose\n2) Glycated hemoglobin\n3) Other carbohydrates (e.g. lactate) ",
      "ceterms:targetNodeName": "A. Carbohydrates"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 1. Carbohydrates, Acid Base and Electrolytes ",
      "ceterms:targetNodeDescription": "1) pH, pCO2, pO2\n2) Osmolality, base excess ",
      "ceterms:targetNodeName": "B. Acid Base "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 1. Carbohydrates, Acid Base and Electrolytes ",
      "ceterms:targetNodeDescription": "1) Sodium, potassium, chloride, bicarbonate, anion gap\n2) Calcium, magnesium, phosphorus ",
      "ceterms:targetNodeName": "C. Electrolytes "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 2. Proteins and Other Nitrogen-Containing Compounds",
      "ceterms:targetNodeDescription": "1) Total protein, albumin\n2) Globulins (alpha 1, alpha 2, beta, gamma)\n3) Ferritin, transferrin\n4) Iron and TIBC\n5) Ammonia\n6) Creatinine, BUN\n7) Uric acid\n8) Troponin\n9) Other (e.g., BNP) ",
      "ceterms:targetNodeName": "A. Protein and Other Nitrogen-Containing Compounds "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 2. Proteins and Other Nitrogen-Containing Compounds",
      "ceterms:targetNodeDescription": "1) Hemoglobin (S, fetal, A2, plasma)\n2) Bilirubin, urobilinogen\n3) Other (e.g., myoglobin) ",
      "ceterms:targetNodeName": "B. Heme Derivatives"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 3. Enzymes, Lipids and Lipoproteins ",
      "ceterms:targetNodeDescription": "1) Amylase, lipase\n2) AST, ALT\n3) CK, LD\n4) ALP\n5) GGT\n6) Other",
      "ceterms:targetNodeName": "A. Enzymes "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 3. Enzymes, Lipids and Lipoproteins ",
      "ceterms:targetNodeDescription": "1) Cholesterol (total, HDL, LDL)\n2) Triglycerides\n3) Phospholipids (PG)\n4) Other lipids and lipoproteins ",
      "ceterms:targetNodeName": "B. Lipids and Lipoproteins "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 4. Special Chemistry (Endocrinology, Tumor Markers, TDM, Toxicology) ",
      "ceterms:targetNodeDescription": "1) T3, T4, TBG, TSH\n2) hCG, FSH, LH, estradiol\n3) Other hormones (e.g. cortisol)\n4) Tumor markers (e.g., alpha fetoprotein, CEA, hCG, PSA)",
      "ceterms:targetNodeName": "A. Endocrinology and Tumor Markers "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "CHEMISTRY (17-22% of total exam) - 4. Special Chemistry (Endocrinology, Tumor Markers, TDM, Toxicology) ",
      "ceterms:targetNodeDescription": "1) Therapeutic drug monitoring\n2) Drugs of abuse\n3) Other toxicology (e.g., carbon monoxide) ",
      "ceterms:targetNodeName": "B. TDM and Toxicology "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 1. Erythrocytes and Leukocytes",
      "ceterms:targetNodeDescription": "1) RBC count\n2) Hemoglobin, hematocrit and indices",
      "ceterms:targetNodeName": "A. Red Blood Cells and Indices "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 1. Erythrocytes and Leukocytes",
      "ceterms:targetNodeDescription": "1) WBC count\n2) Cytochemical stains (e.g., esterases, myeloperoxidase, TdT) ",
      "ceterms:targetNodeName": "B. White Blood Cells"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 1. Erythrocytes and Leukocytes",
      "ceterms:targetNodeName": "C. CBC (includes count, morphology and/or differential) "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 2. Other Tests ",
      "ceterms:targetNodeName": "A. Reticulocyte Count and Other RBC Inclusions "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 2. Other Tests ",
      "ceterms:targetNodeName": "B. ESR "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 2. Other Tests ",
      "ceterms:targetNodeDescription": "1) Sickle cell tests\n2) Hemoglobin electrophoresis ",
      "ceterms:targetNodeName": "C. Tests for Hemoglobin Defects "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 2. Other Tests ",
      "ceterms:targetNodeName": "D. RBC enzymes (e.g. G-6PD) "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 2. Other Tests ",
      "ceterms:targetNodeName": "E. Other (e.g., immunophenotyping, cytogenetics) "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 3. Morphology and Differentials ",
      "ceterms:targetNodeName": "A. Red Blood Cell Morphology "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 3. Morphology and Differentials ",
      "ceterms:targetNodeName": "B. White Blood Cell Morphology "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 3. Morphology and Differentials ",
      "ceterms:targetNodeName": "C. Differential (Whole Blood and Bone Marrow) "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 3. Morphology and Differentials ",
      "ceterms:targetNodeName": "D. Platelet Morphology "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 4. Platelets and Hemostasis  ",
      "ceterms:targetNodeDescription": "1) Platelet count\n2) Platelet function\n3) Disease correlation ",
      "ceterms:targetNodeName": "A. Platelets "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "HEMATOLOGY (17-22% of total exam) - 4. Platelets and Hemostasis  ",
      "ceterms:targetNodeDescription": "1) PT, aPTT, TT\n2) Fibrinogen, FDP, D-dimer\n3) Factor assays\n4) Inhibitor anticoagulants\n5) Mixing studies\n6) Anticoagulant therapy\n7) Hypercoagulability tests\n8) Disease correlation ",
      "ceterms:targetNodeName": "B. Hemostasis"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "IMMUNOLOGY (5-10% of total exam)  - 1. Immunity",
      "ceterms:targetNodeDescription": "1) ANA, anti-DNA\n2) CRP/RF\n3) Thyroid antibodies\n4) Other ",
      "ceterms:targetNodeName": "A. Autoimmunity "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "IMMUNOLOGY (5-10% of total exam)  - 1. Immunity",
      "ceterms:targetNodeName": "B. Immune Responses"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "IMMUNOLOGY (5-10% of total exam)  - 1. Immunity",
      "ceterms:targetNodeName": "C. Physiology of the Immune System "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "IMMUNOLOGY (5-10% of total exam)  - 2. Infectious Diseases ",
      "ceterms:targetNodeDescription": "1) EBV/infectious mononucleosis\n2) Hepatitis\n3) HIV/HTLV/CMV\n4) Rubella/measles\n5) Other viruses ",
      "ceterms:targetNodeName": "A. Viral "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "IMMUNOLOGY (5-10% of total exam)  - 2. Infectious Diseases ",
      "ceterms:targetNodeDescription": "1) Syphilis\n2) Other microorganisms ",
      "ceterms:targetNodeName": "B. Microbial "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeDescription": "A. Pre-Analytical, Analytical, Post-Analytical\nB. Quality Control\nC. Compliance\nD. Regulation ",
      "ceterms:targetNodeName": "1. Quality Assessment/Troubleshooting "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "2. Safety "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeDescription": "A. Purchasing\nB. Inventory Control\nC. Competency ",
      "ceterms:targetNodeName": "3. Management "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "4. Laboratory Mathematics"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "5. Instrumentation"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "6. Education and Communication "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "7. Laboratory Information Systems"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "LABORATORY OPERATIONS  (5-10% of total exam) - 1. Quality Assessment/Troubleshooting ",
      "ceterms:targetNodeName": "8. Molecular Techniques "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 1. Aerobic Gram-positive Cocci ",
      "ceterms:targetNodeName": "Aerobic Gram-positive Cocci: Staphylococcus, Streptococcus, Enterococcus, other"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 2. Gram-negative Bacilli ",
      "ceterms:targetNodeName": "A. Enterobacteriaceae (e.g., Citrobacter, Escherichia, Enterobacter, Klebsiella, Morganella, Proteus, Providencia, Salmonella, Serratia, Shigella, Yersinia)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 2. Gram-negative Bacilli ",
      "ceterms:targetNodeName": "B. Other Gram-negative Bacilli (e.g., Acinetobacter, Aeromonas, Bordetella, Brucella, Campylobacter, Eikenella, Francisella, Haemophilus, Helicobacter, Legionella, Pasteurella, Plesiomonas, Pseudomonas, Burkholderia) Stenotrophomonas, Chryseobacterium, Vibrio, HACEK, Bartonella, Capnocytophaga "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 3. Gram-negative Cocci, Gram-positive Bacilli and Anaerobes ",
      "ceterms:targetNodeName": "A. Aerobic Gram-negative Cocci (e.g., Neisseria, Moraxella) "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 3. Gram-negative Cocci, Gram-positive Bacilli and Anaerobes ",
      "ceterms:targetNodeName": "B. Aerobic or Facultative Gram-positive Bacilli (e.g., Bacillus, Corynebacterium, Erysipelothrix Gardnerella, Lactobacillus, Listeria, Nocardia, Streptomyces)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 3. Gram-negative Cocci, Gram-positive Bacilli and Anaerobes ",
      "ceterms:targetNodeDescription": "1) Gram-positive (e.g., Bifidobacterium, Clostridium, Eubacterium, Actinomyces, Peptostreptococcus, Propionibacterium)\n2) Gram-negative (e.g., Bacteroides, Fusobacterium, Porphyromonas, Prevotella, Veillonella)",
      "ceterms:targetNodeName": "C. Anaerobes "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 4. Fungus, Viruses, Mycobacteria and Parasites",
      "ceterms:targetNodeDescription": " Fungi\n1) Yeast (e.g., Candida, Cryptococcus, Geotrichum, Malassezia)\n2) Dimorphic fungi (e.g., Blastomyces, Coccidioides, Histoplasma, Sporothrix)\n3) Dermatophytes (e.g., Epidermophyton, Microsporum, Trichophyton)\n4) Zygomycetes (e.g., Absidia, Mucor, Rhizopus)\n5) Opportunistic molds/septate hyaline molds (e.g., Aspergillus, Penicillium)\n6) Dematiaceous molds\n7) Pneumocystis",
      "ceterms:targetNodeName": "A. Fungi "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 4. Fungus, Viruses, Mycobacteria and Parasites",
      "ceterms:targetNodeDescription": " Mycobacteria\n1) Mycobacterium tuberculosis complex (e.g., M. tuberculosis)\n2) Other Mycobacteria (e.g., M. aviumintracellulare, rapid growers, M. gordonae, M. kansasii, M. leprae, M. marinum, M. scrofulaceum) ",
      "ceterms:targetNodeName": "B. Mycobacteria "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 4. Fungus, Viruses, Mycobacteria and Parasites",
      "ceterms:targetNodeDescription": "1) Viruses (e.g., specimen collection/transport/processing, cell culture, rapid antigen detection) \n2) Other microorganisms (e.g., Chlamydia, Mycoplasma) ",
      "ceterms:targetNodeName": "C. Viruses and Other Microorganisms "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "MICROBIOLOGY (17-22% of total exam) - 4. Fungus, Viruses, Mycobacteria and Parasites",
      "ceterms:targetNodeDescription": "1) Blood and tissue protozoa (e.g., Plasmodium, Trypanosoma)\n2) Intestinal and urogenital protozoa (e.g., Cryptosporidium, Entamoeba, Giardia, Trichomonas)\n3) Intestinal and tissue helminths (e.g., Ascaris, Enterobius, hookworm, Schistosoma, Strongyloides, Taenia, Trichinella, Trichuris) ",
      "ceterms:targetNodeName": "D. Parasites "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 1. Urinalysis ",
      "ceterms:targetNodeDescription": "1) Color and clarity\n2) Specific gravity/osmolality ",
      "ceterms:targetNodeName": "A. Physical "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 1. Urinalysis ",
      "ceterms:targetNodeDescription": "1) Reagent strip\n2) Confirmatory tests ",
      "ceterms:targetNodeName": "B. Chemical "
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 1. Urinalysis ",
      "ceterms:targetNodeDescription": "1) Cells\n2) Casts\n3) Crystals\n4) Contaminants\n5) Artifacts/microorganisms ",
      "ceterms:targetNodeName": "C. Microscopic"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 1. Urinalysis ",
      "ceterms:targetNodeName": "D. Physiology"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 2. Other Body Fluids (Qualitative & Quantitative) ",
      "ceterms:targetNodeName": "A. CSF"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "https://www.ascp.org/content/docs/default-source/boc-pdfs/boc-us-guidelines/mls_imls_content_guideline_formatted_9-14.pdf?sfvrsn=4",
      "ceterms:frameworkName": "URINALYSIS & OTHER BODY FLUIDS  (5-10% of total exam) - 2. Other Body Fluids (Qualitative & Quantitative) ",
      "ceterms:targetNodeName": "B. Amniotic, Synovial, Serous, Semen and Feces "
    }
  ],
  "ceterms:assessmentMethodType": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "ceterms:AssessmentMethod",
      "ceterms:targetNode": "assessMethod:Exam",
      "ceterms:targetNodeName": "Exam"
    }
  ],
  "ceterms:assessmentUseType": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "ceterms:AssessmentUse",
      "ceterms:targetNode": "assessUse:Summative",
      "ceterms:targetNodeName": "Summative Assessment"
    }
  ],
  "ceterms:availableOnlineAt": [
    "http://www.pearsonvue.com/ascp"
  ],
  "ceterms:ctid": "ce-FA703602-05DA-4C4A-BD96-A2A40148AD15",
  "ceterms:deliveryType": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "Delivery",
      "ceterms:targetNode": "deliveryType:OnlineOnly",
      "ceterms:targetNodeName": "Online Only"
    }
  ],
  "ceterms:description": "All certification examination questions are multiple-choice with one best answer. The examinees will be asked questions that test three types of cognitive skills: recall, application, and analysis. The MLS exam consists of 100 multiple choice questions.\n\nIt is strongly recommended that you contact Pearson registration as early as possible to make your appointment within the three-month examination period. After you have made your appointment, a confirmation letter will be emailed to you. The confirmation letter is not required to sit for the examination.\nYou must take the examination within the three-month examination period indicated on your Admission Notice. Personal/family-related responsibilities or lack of study opportunity will not be considered reasons to cancel, not appear, or miss your scheduled appointment date.",
  "ceterms:estimatedCost": [
    {
      "@type": "ceterms:CostProfile",
      "ceterms:audienceType": [
        {
          "@type": "ceterms:CredentialAlignmentObject",
          "ceterms:framework": "Audience",
          "ceterms:targetNode": "audience:Member",
          "ceterms:targetNodeName": "Member"
        }
      ],
      "ceterms:costDetails": "https://www.ascp.org/content/board-of-certification/get-credentialed/",
      "ceterms:currency": "US Dollar",
      "ceterms:description": "Note: Application fees are non-refundable.\n\n",
      "ceterms:directCostType": [
        {
          "@type": "ceterms:CredentialAlignmentObject",
          "ceterms:framework": "CostType",
          "ceterms:targetNode": "costType:Application",
          "ceterms:targetNodeName": "Application"
        }
      ],
      "ceterms:name": "Application Fee",
      "ceterms:price": 240.00
    }
  ],
  "ceterms:estimatedDuration": [
    {
      "@type": "ceterms:DurationProfile",
      "ceterms:exactDuration": "PT2H30M"
    }
  ],
  "ceterms:hasGroupEvaluation": false,
  "ceterms:hasGroupParticipation": false,
  "ceterms:inLanguage": "English",
  "ceterms:isProctored": false,
  "ceterms:name": "Medical Laboratory Scientist (MLS)",
  "ceterms:scoringMethodType": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:framework": "ceterms:ScoringMethod",
      "ceterms:targetNode": "score:CriterionReferenced",
      "ceterms:targetNodeName": "Criterion-Referenced"
    }
  ],
  "ceterms:subject": [
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Blood Bank (BBNK)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Chemistry (CHEM)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Hematology (HEMA)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Immunology (IMMU)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Laboratory Operations (LO)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Microbiology (MICR)"
    },
    {
      "@type": "ceterms:CredentialAlignmentObject",
      "ceterms:targetNodeName": "Urinalysis and Other Body Fluids (UA)"
    }
  ],
  "ceterms:subjectWebpage": "https://www.ascp.org/content/board-of-certification/get-credentialed"
}